| Literature DB >> 24681140 |
Luis Nombela-Franco1, Henrique Barbosa Ribeiro2, Marina Urena2, Ricardo Allende2, Ignacio Amat-Santos2, Robert DeLarochellière2, Eric Dumont2, Daniel Doyle2, Hugo DeLarochellière2, Jerôme Laflamme2, Louis Laflamme2, Eulogio García3, Carlos Macaya3, Pilar Jiménez-Quevedo3, Mélanie Côté2, Sebastien Bergeron2, Jonathan Beaudoin2, Philippe Pibarot2, Josep Rodés-Cabau4.
Abstract
Significant mitral regurgitation (MR) is frequent in patients with severe aortic stenosis (AS). In these cases, concomitant mitral valve repair or replacement is usually performed at the time of surgical aortic valve replacement (SAVR). Transcatheter aortic valve replacement (TAVR) has recently been considered as an alternative for patients at high or prohibitive surgical risk. However, concomitant significant MR in this setting is typically left untreated. Moderate to severe MR after aortic valve replacement is therefore a relevant entity in the TAVR era. The purpose of this review is to present the current knowledge on the clinical impact and post-procedural evolution of concomitant significant MR in patients with severe AS who have undergone aortic valve replacement (SAVR and TAVR). This information could contribute to improving both the clinical decision-making process in and management of this challenging group of patients.Entities:
Keywords: aortic stenosis; mitral regurgitation; percutaneous therapy; transcatheter aortic valve implantation
Mesh:
Year: 2014 PMID: 24681140 DOI: 10.1016/j.jacc.2014.02.573
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094